Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
about
Human inter-individual variability in metabolism and genotoxic response to zidovudineThe PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsFetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancyElevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Zidovudine and Lamivudine for HIV Infection.Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs)Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.Inhibition of NF-κB activation sensitizes U937 cells to 3'-azido-3'-deoxythymidine induced apoptosisRole of nucleotide excision repair and p53 in zidovudine (AZT)-induced centrosomal deregulation.Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.Transplacental carcinogenesis with dibenzo[def,p]chrysene (DBC): timing of maternal exposures determines target tissue response in offspring.German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008Lung cancer in HIV infected patients: facts, questions and challenges.Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infantsRelevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy.Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of ageSafety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy.Lung Malignancies in HIV Infection.Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress.A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.The genetic toxicity effects of lamivudine and stavudine antiretroviral agents.Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead.Cardiomyocytes are Protected from Antiretroviral Nucleoside Analog-Induced Mitochondrial Toxicity by Overexpression of PGC-1α.Selective protection of zidovudine-induced DNA-damage by the antioxidants WR-1065 and tempol.The stress response resolution assay. I. Quantitative assessment of environmental agent/condition effects on cellular stress resolution outcomes in epithelium.Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs).Mitochondrial compromise in 3-year old patas monkeys exposed in utero to human-equivalent antiretroviral therapies.A computational model of mitochondrial AZT metabolism.Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France.In utero exposure to antiretroviral therapy: feasibility of long-term follow-up
P2860
Q23918962-48F6449E-E2E5-4C9F-946D-1D22D9075705Q26744617-0930AF17-8F87-4094-BD88-3301B04C644DQ28088783-44031048-1EE5-47FB-8F2C-3727FE2B91D3Q33278421-E35FFEB3-BB09-45D3-A38B-2B8540C237B1Q33839401-B425CDAC-0F49-4F0F-9F46-3AA9E564C4E3Q34181048-783AEED0-1369-408A-A522-88E09DDD92FEQ34194561-7A7CD806-9257-41F4-BF1E-B81292D4CDEDQ34200645-460326D4-57ED-4CEA-B1BF-68575061463BQ34440361-B558602B-9274-47F9-9393-969C74D543D5Q34561763-79CB5599-9C5F-4456-8880-6EE10E872588Q35215308-DEB2BD5E-5557-4AAA-90F2-36B99A5480E5Q35327135-6474BFB7-FA08-4D45-885B-E8B2EE118DE4Q35394336-82615BE9-80FA-4684-9AF6-A7C4542128B0Q35718047-4FE14FB9-3291-4213-8C22-CB27CDB93E67Q35960319-F445E8B4-8398-441D-A890-AF4964D06EB4Q36237964-85632280-EBED-45D9-9EBD-9D4848CECA79Q36333957-B387A889-FBE0-476F-9C59-E3F1B8182466Q36748898-30292F58-AF69-4E86-9E40-781EEE64D7ACQ36936334-DC86BBA8-2316-4D73-815F-FCBBB0C93609Q37045192-EFC9F3F4-3949-448C-A750-AB3EBE24DDC6Q37111533-564D24CE-C388-419A-A804-D649594BEA03Q37478443-93C479B7-A398-411B-BD3F-8FA83EAB0434Q37552456-EDBD5C3D-28AB-4252-92CB-5E559F6ADA85Q37588728-704DC1D7-7C66-4702-96BB-AAC193F3601EQ37727229-F8A94DF8-5D73-48D1-97D2-EB744DA97719Q38201765-F933B688-DD1E-4CE9-8648-2560F147A91EQ38942113-884448B2-1CFA-40DA-9AEE-DD277D7DF7E3Q38994464-22515108-41E0-46F2-AB1C-E8C3544C0006Q39171826-E44B701C-331B-4734-959C-95BE89F5637BQ39428374-2C322028-9706-487A-B1FB-FC998C096141Q39565701-DDC4AFCD-4AF9-443B-9A8E-42E031C505C6Q40678103-BE176551-F0D9-4E7F-AC90-A0E9B459D87DQ44097186-4FB69FB2-5DB9-4519-9FD8-EC28C8383535Q44684894-8A739835-5AC3-44C0-94AC-8AA9B7AA1F31Q57076304-1BFDEDF3-8E7B-4244-A4A7-5EB77CF82049
P2860
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@ast
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@en
type
label
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@ast
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@en
prefLabel
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@ast
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@en
P2093
P1476
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
@en
P2093
Dale M Walker
Miriam C Poirier
Ofelia A Olivero
Vernon E Walker
P304
P356
10.1016/J.TAAP.2003.11.034
P577
2004-09-01T00:00:00Z